文献速递头颈与中枢神经肿瘤

血小板减少限制复发胶质母细胞瘤挽救性洛莫司汀化疗可行性:EORTC 26101二次分析

Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
PubMed 文献 · Eur J Cancer · 2022-10-20

该研究为EORTC 26101随机试验的回顾性分析,评估复发胶质母细胞瘤中洛莫司汀所致血小板减少的发生率及其对治疗暴露和生存的影响。共225例单用洛莫司汀(中位1周期)和283例洛莫司汀联合贝伐珠单抗(中位3周期洛莫司汀周期)。血小板减少是剂量延迟和减量的首要原因;因血小板减少调整剂量与MGMT启动子甲基化患者无进展生存期较差相关,总生存期仅在联合组中观察到该效应。

要点

  • 血小板减少是洛莫司汀剂量延迟和减量的首要原因。
  • 单药组57%、联合组66%患者发生至少一次血小板减少。
  • 因血小板减少调整剂量与MGMT启动子甲基化患者无进展生存期较差相关。

核心结论

  • 药物性血小板减少是复发胶质母细胞瘤中洛莫司汀化疗充分暴露的主要限制。
  • 减轻血小板减少以提高洛莫司汀暴露可能改善MGMT启动子甲基化患者的结局。

研究设计与样本

  • EORTC 26101随机试验的回顾性分析,该试验旨在明确复发胶质母细胞瘤中洛莫司汀对比贝伐珠单抗及两者联合的作用。
  • 组1共225例患者接受洛莫司汀单药治疗(中位1周期)。
  • 组2共283例患者接受洛莫司汀联合贝伐珠单抗治疗(中位3个洛莫司汀周期)。

主要发现

  • 在因毒性导致的洛莫司汀周期延迟和剂量减少中,血小板减少是首要原因。
  • 组1中129例(57%)患者、组2中187例(66%)患者发生至少一次血小板减少。
  • 组1中36例(16%)患者、组2中93例(33%)患者因血小板减少而调整治疗。
  • 组1中16例(7.1%)患者、组2中38例(13.4%)患者因血小板减少停用洛莫司汀。
  • 校正主要预后因素后,因血小板减少调整剂量与组1和组2中MGMT启动子甲基化患者的无进展生存期较差相关;总生存期也观察到该效应,但仅限于组2患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombocytopenia represents the main cause of stopping alkylating chemotherapy for toxicity. Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma. METHODS: We performed a retrospective analysis of the associations of thrombocytopenia with treatment delivery and outcome in EORTC 26101, a randomised trial designed to define the role of lomustine versus bevacizumab versus their combination in recurrent glioblastoma. RESULTS: A total of 225 patients were treated with lomustine alone (median 1 cycle) (group 1) and 283 patients were treated with lomustine plus bevacizumab (median 3 lomustine cycles) (group 2). Among cycle delays and dose reductions of lomustine for toxicity, thrombocytopenia was the leading cause. Among 129 patients (57%) of group 1 and 187 patients (66%) of group 2 experiencing at least one episode of thrombocytopenia, 36 patients (16%) in group 1 and 93 (33%) in group 2 had their treatment modified because of thrombocytopenia. Lomustine was discontinued for thrombocytopenia in 16 patients (7.1%) in group 1 and in 38 patients (13.4%) in group 2. On adjusted analysis accounting for major prognostic factors, dose modification induced by thrombocytopenia was associated with inferior progression-free survival in patients with MGMT promoter-methylated tumours in groups 1 and 2. This effect was noted for overall survival, too, but only for group 2 patients. CONCLUSION: Drug-induced thrombocytopenia is a major limitation to adequate exposure to lomustine chemotherapy in recurrent glioblastoma. Mitigating thrombocytopenia to enhance lomustine exposure might improve outcome in patients with MGMT promoter-methylated tumours.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Le Rhun E, Oppong FB, van den Bent M, et al. Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. Eur J Cancer. 2022. PMID: 36379185. doi:10.1016/j.ejca.2022.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。